#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0956] As is also disclosed in U.S.
1-1	0-1	[	_	_	
1-2	1-5	0956	_	_	
1-3	5-6	]	_	_	
1-4	7-9	As	_	_	
1-5	10-12	is	_	_	
1-6	13-17	also	_	_	
1-7	18-27	disclosed	_	_	
1-8	28-30	in	_	_	
1-9	31-34	U.S	_	_	
1-10	34-35	.	_	_	

#Text=Pat.
2-1	36-39	Pat	_	_	
2-2	39-40	.	_	_	

#Text=No. 6,017,958, "On the basis of these experiments, it can be seen that thyroxine type analogues, such as DIME, are capable of blocking mitosis in cancer cells.
3-1	41-43	No	_	_	
3-2	43-44	.	_	_	
3-3	45-54	6,017,958	_	_	
3-4	54-55	,	_	_	
3-5	56-57	"	_	_	
3-6	57-59	On	_	_	
3-7	60-63	the	_	_	
3-8	64-69	basis	_	_	
3-9	70-72	of	_	_	
3-10	73-78	these	_	_	
3-11	79-90	experiments	_	_	
3-12	90-91	,	_	_	
3-13	92-94	it	_	_	
3-14	95-98	can	_	_	
3-15	99-101	be	_	_	
3-16	102-106	seen	_	_	
3-17	107-111	that	_	_	
3-18	112-121	thyroxine	_	_	
3-19	122-126	type	_	_	
3-20	127-136	analogues	_	_	
3-21	136-137	,	_	_	
3-22	138-142	such	_	_	
3-23	143-145	as	_	_	
3-24	146-150	DIME	_	_	
3-25	150-151	,	_	_	
3-26	152-155	are	_	_	
3-27	156-163	capable	_	_	
3-28	164-166	of	_	_	
3-29	167-175	blocking	_	_	
3-30	176-183	mitosis	_	_	
3-31	184-186	in	_	_	
3-32	187-193	cancer	_	_	
3-33	194-199	cells	_	_	
3-34	199-200	.	_	_	

#Text=The present invention provides for a rapid screen for such compounds by use of these techniques and use of cell sorters, chromosome blot or other analysis of DNA in cells."
4-1	201-204	The	_	_	
4-2	205-212	present	_	_	
4-3	213-222	invention	_	_	
4-4	223-231	provides	_	_	
4-5	232-235	for	_	_	
4-6	236-237	a	_	_	
4-7	238-243	rapid	_	_	
4-8	244-250	screen	_	_	
4-9	251-254	for	_	_	
4-10	255-259	such	_	_	
4-11	260-269	compounds	_	_	
4-12	270-272	by	_	_	
4-13	273-276	use	_	_	
4-14	277-279	of	_	_	
4-15	280-285	these	_	_	
4-16	286-296	techniques	_	_	
4-17	297-300	and	_	_	
4-18	301-304	use	_	_	
4-19	305-307	of	_	_	
4-20	308-312	cell	_	_	
4-21	313-320	sorters	_	_	
4-22	320-321	,	_	_	
4-23	322-332	chromosome	_	_	
4-24	333-337	blot	_	_	
4-25	338-340	or	_	_	
4-26	341-346	other	_	_	
4-27	347-355	analysis	_	_	
4-28	356-358	of	_	_	
4-29	359-362	DNA	_	_	
4-30	363-365	in	_	_	
4-31	366-371	cells	_	_	
4-32	371-372	.	_	_	
4-33	372-373	"	_	_	

#Text=One may selectively use one or more of such thyroxine type analogs, during part or all of the reaction process, to selectively inhibit tubulin assembly.
#Text=[0957] By way of further illustration, U.S.
5-1	374-377	One	_	_	
5-2	378-381	may	_	_	
5-3	382-393	selectively	_	_	
5-4	394-397	use	_	_	
5-5	398-401	one	_	_	
5-6	402-404	or	_	_	
5-7	405-409	more	_	_	
5-8	410-412	of	_	_	
5-9	413-417	such	_	_	
5-10	418-427	thyroxine	_	_	
5-11	428-432	type	_	_	
5-12	433-440	analogs	_	_	
5-13	440-441	,	_	_	
5-14	442-448	during	_	_	
5-15	449-453	part	_	_	
5-16	454-456	or	_	_	
5-17	457-460	all	_	_	
5-18	461-463	of	_	_	
5-19	464-467	the	_	_	
5-20	468-476	reaction	_	_	
5-21	477-484	process	_	_	
5-22	484-485	,	_	_	
5-23	486-488	to	_	_	
5-24	489-500	selectively	_	_	
5-25	501-508	inhibit	_	_	
5-26	509-516	tubulin	_	_	
5-27	517-525	assembly	_	_	
5-28	525-526	.	_	_	
5-29	527-528	[	_	_	
5-30	528-532	0957	_	_	
5-31	532-533	]	_	_	
5-32	534-536	By	_	_	
5-33	537-540	way	_	_	
5-34	541-543	of	_	_	
5-35	544-551	further	_	_	
5-36	552-564	illustration	_	_	
5-37	564-565	,	_	_	
5-38	566-569	U.S	_	_	
5-39	569-570	.	_	_	

#Text=Pat.
6-1	571-574	Pat	_	_	
6-2	574-575	.	_	_	

#Text=No. 6,326,402 discloses that a diiodo thyronine analog binds a microtubule.
7-1	576-578	No	_	_	
7-2	578-579	.	_	_	
7-3	580-589	6,326,402	_	_	
7-4	590-599	discloses	_	_	
7-5	600-604	that	_	_	
7-6	605-606	a	_	_	
7-7	607-613	diiodo	_	_	
7-8	614-623	thyronine	_	_	
7-9	624-630	analog	_	_	
7-10	631-636	binds	_	_	
7-11	637-638	a	_	_	
7-12	639-650	microtubule	_	_	
7-13	650-651	.	_	_	

#Text=The entire disclosure of this United States patent is hereby incorporated by reference into this specification.
8-1	652-655	The	_	_	
8-2	656-662	entire	_	_	
8-3	663-673	disclosure	_	_	
8-4	674-676	of	_	_	
8-5	677-681	this	_	_	
8-6	682-688	United	_	_	
8-7	689-695	States	_	_	
8-8	696-702	patent	_	_	
8-9	703-705	is	_	_	
8-10	706-712	hereby	_	_	
8-11	713-725	incorporated	_	_	
8-12	726-728	by	_	_	
8-13	729-738	reference	_	_	
8-14	739-743	into	_	_	
8-15	744-748	this	_	_	
8-16	749-762	specification	_	_	
8-17	762-763	.	_	_	

#Text=One may use such as diiodo thyronine analog as a reagent in the processes depicted in FIGS. 7, 8A, and/or 8B.
#Text=[0958] An experiment designed to determine the effect of discodermolide (and its analogs) upon tubulin polymerization was disclosed at columns 20-21 of U.S.
9-1	764-767	One	_	_	
9-2	768-771	may	_	_	
9-3	772-775	use	_	_	
9-4	776-780	such	_	_	
9-5	781-783	as	_	_	
9-6	784-790	diiodo	_	_	
9-7	791-800	thyronine	_	_	
9-8	801-807	analog	_	_	
9-9	808-810	as	_	_	
9-10	811-812	a	_	_	
9-11	813-820	reagent	_	_	
9-12	821-823	in	_	_	
9-13	824-827	the	_	_	
9-14	828-837	processes	_	_	
9-15	838-846	depicted	_	_	
9-16	847-849	in	_	_	
9-17	850-854	FIGS	_	_	
9-18	854-855	.	_	_	
9-19	856-857	7	_	_	
9-20	857-858	,	_	_	
9-21	859-861	8A	_	_	
9-22	861-862	,	_	_	
9-23	863-866	and	_	_	
9-24	866-867	/	_	_	
9-25	867-869	or	_	_	
9-26	870-872	8B	_	_	
9-27	872-873	.	_	_	
9-28	874-875	[	_	_	
9-29	875-879	0958	_	_	
9-30	879-880	]	_	_	
9-31	881-883	An	_	_	
9-32	884-894	experiment	_	_	
9-33	895-903	designed	_	_	
9-34	904-906	to	_	_	
9-35	907-916	determine	_	_	
9-36	917-920	the	_	_	
9-37	921-927	effect	_	_	
9-38	928-930	of	_	_	
9-39	931-945	discodermolide	_	_	
9-40	946-947	(	_	_	
9-41	947-950	and	_	_	
9-42	951-954	its	_	_	
9-43	955-962	analogs	_	_	
9-44	962-963	)	_	_	
9-45	964-968	upon	_	_	
9-46	969-976	tubulin	_	_	
9-47	977-991	polymerization	_	_	
9-48	992-995	was	_	_	
9-49	996-1005	disclosed	_	_	
9-50	1006-1008	at	_	_	
9-51	1009-1016	columns	_	_	
9-52	1017-1019	20	_	_	
9-53	1019-1020	-	_	_	
9-54	1020-1022	21	_	_	
9-55	1023-1025	of	_	_	
9-56	1026-1029	U.S	_	_	
9-57	1029-1030	.	_	_	

#Text=Pat.
10-1	1031-1034	Pat	_	_	
10-2	1034-1035	.	_	_	

#Text=No. 6,495,594, the entire disclosure of which is hereby incorporated by reference into this specification.
11-1	1036-1038	No	_	_	
11-2	1038-1039	.	_	_	
11-3	1040-1049	6,495,594	_	_	
11-4	1049-1050	,	_	_	
11-5	1051-1054	the	_	_	
11-6	1055-1061	entire	_	_	
11-7	1062-1072	disclosure	_	_	
11-8	1073-1075	of	_	_	
11-9	1076-1081	which	_	_	
11-10	1082-1084	is	_	_	
11-11	1085-1091	hereby	_	_	
11-12	1092-1104	incorporated	_	_	
11-13	1105-1107	by	_	_	
11-14	1108-1117	reference	_	_	
11-15	1118-1122	into	_	_	
11-16	1123-1127	this	_	_	
11-17	1128-1141	specification	_	_	
11-18	1141-1142	.	_	_	

#Text=As is disclosed in this patent, "Polymerization of purified bovine brain tubulin (Cytoskeleton Inc., Denver, Colo.) was followed by changes in the optical density of tubulin solutions at 350 nm in a Hitachi U-3010 spectrophotometer equipped with a SPR-10 electronic thermostatted cell holder.
12-1	1143-1145	As	_	_	
12-2	1146-1148	is	_	_	
12-3	1149-1158	disclosed	_	_	
12-4	1159-1161	in	_	_	
12-5	1162-1166	this	_	_	
12-6	1167-1173	patent	_	_	
12-7	1173-1174	,	_	_	
12-8	1175-1176	"	_	_	
12-9	1176-1190	Polymerization	_	_	
12-10	1191-1193	of	_	_	
12-11	1194-1202	purified	_	_	
12-12	1203-1209	bovine	_	_	
12-13	1210-1215	brain	_	_	
12-14	1216-1223	tubulin	_	_	
12-15	1224-1225	(	_	_	
12-16	1225-1237	Cytoskeleton	_	_	
12-17	1238-1241	Inc	_	_	
12-18	1241-1242	.	_	_	
12-19	1242-1243	,	_	_	
12-20	1244-1250	Denver	_	_	
12-21	1250-1251	,	_	_	
12-22	1252-1256	Colo	_	_	
12-23	1256-1257	.	_	_	
12-24	1257-1258	)	_	_	
12-25	1259-1262	was	_	_	
12-26	1263-1271	followed	_	_	
12-27	1272-1274	by	_	_	
12-28	1275-1282	changes	_	_	
12-29	1283-1285	in	_	_	
12-30	1286-1289	the	_	_	
12-31	1290-1297	optical	_	_	
12-32	1298-1305	density	_	_	
12-33	1306-1308	of	_	_	
12-34	1309-1316	tubulin	_	_	
12-35	1317-1326	solutions	_	_	
12-36	1327-1329	at	_	_	
12-37	1330-1333	350	_	_	
12-38	1334-1336	nm	_	_	
12-39	1337-1339	in	_	_	
12-40	1340-1341	a	_	_	
12-41	1342-1349	Hitachi	_	_	
12-42	1350-1351	U	_	_	
12-43	1351-1352	-	_	_	
12-44	1352-1356	3010	_	_	
12-45	1357-1374	spectrophotometer	_	_	
12-46	1375-1383	equipped	_	_	
12-47	1384-1388	with	_	_	
12-48	1389-1390	a	_	_	
12-49	1391-1394	SPR	_	_	
12-50	1394-1395	-	_	_	
12-51	1395-1397	10	_	_	
12-52	1398-1408	electronic	_	_	
12-53	1409-1422	thermostatted	_	_	
12-54	1423-1427	cell	_	_	
12-55	1428-1434	holder	_	_	
12-56	1434-1435	.	_	_	

#Text=Stock solutions of tubulin were diluted on ice in G-PEM buffer (1 mM GTP, 80 mM PIPES, 1 mM EGTA, 0.5 mM magnesium chloride; pH 6.8) to a final concentration of 1 mg/mL.
13-1	1436-1441	Stock	*[1]	14-6[2_1]	
13-2	1442-1451	solutions	*[1]	_	
13-3	1452-1454	of	*[1]	_	
13-4	1455-1462	tubulin	*[1]	_	
13-5	1463-1467	were	*[1]	_	
13-6	1468-1475	diluted	*[1]	_	
13-7	1476-1478	on	*[1]	_	
13-8	1479-1482	ice	*[1]	_	
13-9	1483-1485	in	*[1]	_	
13-10	1486-1491	G-PEM	*[1]	_	
13-11	1492-1498	buffer	*[1]	_	
13-12	1499-1500	(	*[1]	_	
13-13	1500-1501	1	*[1]	_	
13-14	1502-1504	mM	*[1]	_	
13-15	1505-1508	GTP	*[1]	_	
13-16	1508-1509	,	*[1]	_	
13-17	1510-1512	80	*[1]	_	
13-18	1513-1515	mM	*[1]	_	
13-19	1516-1521	PIPES	*[1]	_	
13-20	1521-1522	,	*[1]	_	
13-21	1523-1524	1	*[1]	_	
13-22	1525-1527	mM	*[1]	_	
13-23	1528-1532	EGTA	*[1]	_	
13-24	1532-1533	,	*[1]	_	
13-25	1534-1537	0.5	*[1]	_	
13-26	1538-1540	mM	*[1]	_	
13-27	1541-1550	magnesium	*[1]	_	
13-28	1551-1559	chloride	*[1]	_	
13-29	1559-1560	;	*[1]	_	
13-30	1561-1563	pH	*[1]	_	
13-31	1564-1567	6.8	*[1]	_	
13-32	1567-1568	)	*[1]	_	
13-33	1569-1571	to	*[1]	_	
13-34	1572-1573	a	*[1]	_	
13-35	1574-1579	final	*[1]	_	
13-36	1580-1593	concentration	*[1]	_	
13-37	1594-1596	of	*[1]	_	
13-38	1597-1598	1	*[1]	_	
13-39	1599-1601	mg	*[1]	_	
13-40	1601-1602	/	*[1]	_	
13-41	1602-1604	mL	*[1]	_	
13-42	1604-1605	.	*[1]	_	

#Text=The instrument was zeroed on this solution at 4.degree.
14-1	1606-1609	The	_	_	
14-2	1610-1620	instrument	_	_	
14-3	1621-1624	was	_	_	
14-4	1625-1631	zeroed	_	_	
14-5	1632-1634	on	_	_	
14-6	1635-1639	this	*[2]	_	
14-7	1640-1648	solution	*[2]	_	
14-8	1649-1651	at	_	_	
14-9	1652-1653	4	_	_	
14-10	1653-1654	.	_	_	
14-11	1654-1660	degree	_	_	
14-12	1660-1661	.	_	_	

#Text=C.
15-1	1662-1663	C	_	_	
15-2	1663-1664	.	_	_	

#Text=Discodermolide, and its analogs, were then added to the tubulin solution to a final concentration of 10 .mu.M, quickly mixed, and the absorbance monitored over a period of 61 minutes.
16-1	1665-1679	Discodermolide	_	_	
16-2	1679-1680	,	_	_	
16-3	1681-1684	and	_	_	
16-4	1685-1688	its	_	_	
16-5	1689-1696	analogs	_	_	
16-6	1696-1697	,	_	_	
16-7	1698-1702	were	_	_	
16-8	1703-1707	then	_	_	
16-9	1708-1713	added	_	_	
16-10	1714-1716	to	_	_	
16-11	1717-1720	the	_	_	
16-12	1721-1728	tubulin	_	_	
16-13	1729-1737	solution	_	_	
16-14	1738-1740	to	_	_	
16-15	1741-1742	a	_	_	
16-16	1743-1748	final	_	_	
16-17	1749-1762	concentration	_	_	
16-18	1763-1765	of	_	_	
16-19	1766-1768	10	_	_	
16-20	1769-1770	.	_	_	
16-21	1770-1774	mu.M	_	_	
16-22	1774-1775	,	_	_	
16-23	1776-1783	quickly	_	_	
16-24	1784-1789	mixed	_	_	
16-25	1789-1790	,	_	_	
16-26	1791-1794	and	_	_	
16-27	1795-1798	the	_	_	
16-28	1799-1809	absorbance	_	_	
16-29	1810-1819	monitored	_	_	
16-30	1820-1824	over	_	_	
16-31	1825-1826	a	_	_	
16-32	1827-1833	period	_	_	
16-33	1834-1836	of	_	_	
16-34	1837-1839	61	_	_	
16-35	1840-1847	minutes	_	_	
16-36	1847-1848	.	_	_	

#Text=Within this time the temperature of the thermoelectric cell holder was held at 4.degree.
17-1	1849-1855	Within	_	_	
17-2	1856-1860	this	_	_	
17-3	1861-1865	time	_	_	
17-4	1866-1869	the	_	_	
17-5	1870-1881	temperature	_	_	
17-6	1882-1884	of	_	_	
17-7	1885-1888	the	_	_	
17-8	1889-1903	thermoelectric	_	_	
17-9	1904-1908	cell	_	_	
17-10	1909-1915	holder	_	_	
17-11	1916-1919	was	_	_	
17-12	1920-1924	held	_	_	
17-13	1925-1927	at	_	_	
17-14	1928-1929	4	_	_	
17-15	1929-1930	.	_	_	
17-16	1930-1936	degree	_	_	
17-17	1936-1937	.	_	_	

#Text=C. for 1 minute, increased to 35.degree.
18-1	1938-1939	C	_	_	
18-2	1939-1940	.	_	_	
18-3	1941-1944	for	_	_	
18-4	1945-1946	1	_	_	
18-5	1947-1953	minute	_	_	
18-6	1953-1954	,	_	_	
18-7	1955-1964	increased	_	_	
18-8	1965-1967	to	_	_	
18-9	1968-1970	35	_	_	
18-10	1970-1971	.	_	_	
18-11	1971-1977	degree	_	_	
18-12	1977-1978	.	_	_	

#Text=C. at a rate of 1.degree.
19-1	1979-1980	C	_	_	
19-2	1980-1981	.	_	_	
19-3	1982-1984	at	_	_	
19-4	1985-1986	a	_	_	
19-5	1987-1991	rate	_	_	
19-6	1992-1994	of	_	_	
19-7	1995-1996	1	_	_	
19-8	1996-1997	.	_	_	
19-9	1997-2003	degree	_	_	
19-10	2003-2004	.	_	_	

#Text=C.
20-1	2005-2006	C	_	_	
20-2	2006-2007	.	_	_	

#Text=/minute, reduced back to 4.degree.
21-1	2007-2008	/	_	_	
21-2	2008-2014	minute	_	_	
21-3	2014-2015	,	_	_	
21-4	2016-2023	reduced	_	_	
21-5	2024-2028	back	_	_	
21-6	2029-2031	to	_	_	
21-7	2032-2033	4	_	_	
21-8	2033-2034	.	_	_	
21-9	2034-2040	degree	_	_	
21-10	2040-2041	.	_	_	

#Text=C. at a rate of 2.degree.
22-1	2042-2043	C	_	_	
22-2	2043-2044	.	_	_	
22-3	2045-2047	at	_	_	
22-4	2048-2049	a	_	_	
22-5	2050-2054	rate	_	_	
22-6	2055-2057	of	_	_	
22-7	2058-2059	2	_	_	
22-8	2059-2060	.	_	_	
22-9	2060-2066	degree	_	_	
22-10	2066-2067	.	_	_	

#Text=C.
23-1	2068-2069	C	_	_	
23-2	2069-2070	.	_	_	

#Text=/minute, and held at 4.degree.
24-1	2070-2071	/	_	_	
24-2	2071-2077	minute	_	_	
24-3	2077-2078	,	_	_	
24-4	2079-2082	and	_	_	
24-5	2083-2087	held	_	_	
24-6	2088-2090	at	_	_	
24-7	2091-2092	4	_	_	
24-8	2092-2093	.	_	_	
24-9	2093-2099	degree	_	_	
24-10	2099-2100	.	_	_	

#Text=C. for an additional 14 minutes."
#Text=[0959] U.S.
25-1	2101-2102	C	_	_	
25-2	2102-2103	.	_	_	
25-3	2104-2107	for	_	_	
25-4	2108-2110	an	_	_	
25-5	2111-2121	additional	_	_	
25-6	2122-2124	14	_	_	
25-7	2125-2132	minutes	_	_	
25-8	2132-2133	.	_	_	
25-9	2133-2134	"	_	_	
25-10	2135-2136	[	_	_	
25-11	2136-2140	0959	_	_	
25-12	2140-2141	]	_	_	
25-13	2142-2145	U.S	_	_	
25-14	2145-2146	.	_	_	

#Text=Pat.
26-1	2147-2150	Pat	_	_	
26-2	2150-2151	.	_	_	

#Text=No. 6,495,584 also discloses that "Cell cycle studies were initiated in order to pinpoint a specific phase within the cell cycle in which discodermolide analogs were exerting their antiproliferative effect.
27-1	2152-2154	No	_	_	
27-2	2154-2155	.	_	_	
27-3	2156-2165	6,495,584	_	_	
27-4	2166-2170	also	_	_	
27-5	2171-2180	discloses	_	_	
27-6	2181-2185	that	_	_	
27-7	2186-2187	"	_	_	
27-8	2187-2191	Cell	_	_	
27-9	2192-2197	cycle	_	_	
27-10	2198-2205	studies	_	_	
27-11	2206-2210	were	_	_	
27-12	2211-2220	initiated	_	_	
27-13	2221-2223	in	_	_	
27-14	2224-2229	order	_	_	
27-15	2230-2232	to	_	_	
27-16	2233-2241	pinpoint	_	_	
27-17	2242-2243	a	_	_	
27-18	2244-2252	specific	_	_	
27-19	2253-2258	phase	_	_	
27-20	2259-2265	within	_	_	
27-21	2266-2269	the	_	_	
27-22	2270-2274	cell	_	_	
27-23	2275-2280	cycle	_	_	
27-24	2281-2283	in	_	_	
27-25	2284-2289	which	_	_	
27-26	2290-2304	discodermolide	_	_	
27-27	2305-2312	analogs	_	_	
27-28	2313-2317	were	_	_	
27-29	2318-2326	exerting	_	_	
27-30	2327-2332	their	_	_	
27-31	2333-2350	antiproliferative	_	_	
27-32	2351-2357	effect	_	_	
27-33	2357-2358	.	_	_	

#Text=A549 human lung cells were used as cell cycle targets to compare the effects of discodermolide and discodermolide analogs on perturbation of the cell cycle.
28-1	2359-2363	A549	_	_	
28-2	2364-2369	human	_	_	
28-3	2370-2374	lung	_	_	
28-4	2375-2380	cells	_	_	
28-5	2381-2385	were	_	_	
28-6	2386-2390	used	_	_	
28-7	2391-2393	as	_	_	
28-8	2394-2398	cell	_	_	
28-9	2399-2404	cycle	_	_	
28-10	2405-2412	targets	_	_	
28-11	2413-2415	to	_	_	
28-12	2416-2423	compare	_	_	
28-13	2424-2427	the	_	_	
28-14	2428-2435	effects	_	_	
28-15	2436-2438	of	_	_	
28-16	2439-2453	discodermolide	_	_	
28-17	2454-2457	and	_	_	
28-18	2458-2472	discodermolide	_	_	
28-19	2473-2480	analogs	_	_	
28-20	2481-2483	on	_	_	
28-21	2484-2496	perturbation	_	_	
28-22	2497-2499	of	_	_	
28-23	2500-2503	the	_	_	
28-24	2504-2508	cell	_	_	
28-25	2509-2514	cycle	_	_	
28-26	2514-2515	.	_	_	

#Text=Cell cycle analyses were performed as follows: A549 cells were incubated at 37.degree.
29-1	2516-2520	Cell	_	_	
29-2	2521-2526	cycle	_	_	
29-3	2527-2535	analyses	_	_	
29-4	2536-2540	were	_	_	
29-5	2541-2550	performed	_	_	
29-6	2551-2553	as	_	_	
29-7	2554-2561	follows	_	_	
29-8	2561-2562	:	_	_	
29-9	2563-2567	A549	_	_	
29-10	2568-2573	cells	_	_	
29-11	2574-2578	were	_	_	
29-12	2579-2588	incubated	_	_	
29-13	2589-2591	at	_	_	
29-14	2592-2594	37	_	_	
29-15	2594-2595	.	_	_	
29-16	2595-2601	degree	_	_	
29-17	2601-2602	.	_	_	

#Text=C. in 5% CO.sub.2 in air in the presence or absence of varying concentrations of discodermolide or discodermolide analogs for 24 hr.
30-1	2603-2604	C	_	_	
30-2	2604-2605	.	_	_	
30-3	2606-2608	in	_	_	
30-4	2609-2611	5%	_	_	
30-5	2612-2618	CO.sub	_	_	
30-6	2618-2620	.2	_	_	
30-7	2621-2623	in	_	_	
30-8	2624-2627	air	_	_	
30-9	2628-2630	in	_	_	
30-10	2631-2634	the	_	_	
30-11	2635-2643	presence	_	_	
30-12	2644-2646	or	_	_	
30-13	2647-2654	absence	_	_	
30-14	2655-2657	of	_	_	
30-15	2658-2665	varying	_	_	
30-16	2666-2680	concentrations	_	_	
30-17	2681-2683	of	_	_	
30-18	2684-2698	discodermolide	_	_	
30-19	2699-2701	or	_	_	
30-20	2702-2716	discodermolide	_	_	
30-21	2717-2724	analogs	_	_	
30-22	2725-2728	for	_	_	
30-23	2729-2731	24	_	_	
30-24	2732-2734	hr	_	_	
30-25	2734-2735	.	_	_	

#Text=Cells were harvested, fixed in ethanol, washed, and stained with 0.02 mg/mL of propidium iodide (P.I.) together with 0.1 mg/mL of RNAse A.
31-1	2736-2741	Cells	_	_	
31-2	2742-2746	were	_	_	
31-3	2747-2756	harvested	_	_	
31-4	2756-2757	,	_	_	
31-5	2758-2763	fixed	_	_	
31-6	2764-2766	in	_	_	
31-7	2767-2774	ethanol	_	_	
31-8	2774-2775	,	_	_	
31-9	2776-2782	washed	_	_	
31-10	2782-2783	,	_	_	
31-11	2784-2787	and	_	_	
31-12	2788-2795	stained	_	_	
31-13	2796-2800	with	_	_	
31-14	2801-2805	0.02	_	_	
31-15	2806-2808	mg	_	_	
31-16	2808-2809	/	_	_	
31-17	2809-2811	mL	_	_	
31-18	2812-2814	of	_	_	
31-19	2815-2824	propidium	_	_	
31-20	2825-2831	iodide	_	_	
31-21	2832-2833	(	_	_	
31-22	2833-2836	P.I	_	_	
31-23	2836-2837	.	_	_	
31-24	2837-2838	)	_	_	
31-25	2839-2847	together	_	_	
31-26	2848-2852	with	_	_	
31-27	2853-2856	0.1	_	_	
31-28	2857-2859	mg	_	_	
31-29	2859-2860	/	_	_	
31-30	2860-2862	mL	_	_	
31-31	2863-2865	of	_	_	
31-32	2866-2871	RNAse	_	_	
31-33	2872-2873	A	_	_	
31-34	2873-2874	.	_	_	

#Text=Stained preparations were analyzed on a Coulter EPICS ELITE flow cytometer with 488 nM excitation.
32-1	2875-2882	Stained	_	_	
32-2	2883-2895	preparations	_	_	
32-3	2896-2900	were	_	_	
32-4	2901-2909	analyzed	_	_	
32-5	2910-2912	on	_	_	
32-6	2913-2914	a	_	_	
32-7	2915-2922	Coulter	_	_	
32-8	2923-2928	EPICS	_	_	
32-9	2929-2934	ELITE	_	_	
32-10	2935-2939	flow	_	_	
32-11	2940-2949	cytometer	_	_	
32-12	2950-2954	with	_	_	
32-13	2955-2958	488	_	_	
32-14	2959-2961	nM	_	_	
32-15	2962-2972	excitation	_	_	
32-16	2972-2973	.	_	_	

#Text=Fluorescence measurements and resulting DNA histograms were collected from at least 10,000 P.I. stained cells at an emission wavelength of 690 nM.
33-1	2974-2986	Fluorescence	_	_	
33-2	2987-2999	measurements	_	_	
33-3	3000-3003	and	_	_	
33-4	3004-3013	resulting	_	_	
33-5	3014-3017	DNA	_	_	
33-6	3018-3028	histograms	_	_	
33-7	3029-3033	were	_	_	
33-8	3034-3043	collected	_	_	
33-9	3044-3048	from	_	_	
33-10	3049-3051	at	_	_	
33-11	3052-3057	least	_	_	
33-12	3058-3064	10,000	_	_	
33-13	3065-3068	P.I	_	_	
33-14	3068-3069	.	_	_	
33-15	3070-3077	stained	_	_	
33-16	3078-3083	cells	_	_	
33-17	3084-3086	at	_	_	
33-18	3087-3089	an	_	_	
33-19	3090-3098	emission	_	_	
33-20	3099-3109	wavelength	_	_	
33-21	3110-3112	of	_	_	
33-22	3113-3116	690	_	_	
33-23	3117-3119	nM	_	_	
33-24	3119-3120	.	_	_	

#Text=Raw histogram data was further analyzed using a cell cycle analysis program (Multicycle, Phoenix Flow Systems)."
#Text=[0960] By way of yet further illustration, and as is disclosed in U.S.
34-1	3121-3124	Raw	_	_	
34-2	3125-3134	histogram	_	_	
34-3	3135-3139	data	_	_	
34-4	3140-3143	was	_	_	
34-5	3144-3151	further	_	_	
34-6	3152-3160	analyzed	_	_	
34-7	3161-3166	using	_	_	
34-8	3167-3168	a	_	_	
34-9	3169-3173	cell	_	_	
34-10	3174-3179	cycle	_	_	
34-11	3180-3188	analysis	_	_	
34-12	3189-3196	program	_	_	
34-13	3197-3198	(	_	_	
34-14	3198-3208	Multicycle	_	_	
34-15	3208-3209	,	_	_	
34-16	3210-3217	Phoenix	_	_	
34-17	3218-3222	Flow	_	_	
34-18	3223-3230	Systems	_	_	
34-19	3230-3231	)	_	_	
34-20	3231-3232	.	_	_	
34-21	3232-3233	"	_	_	
34-22	3234-3235	[	_	_	
34-23	3235-3239	0960	_	_	
34-24	3239-3240	]	_	_	
34-25	3241-3243	By	_	_	
34-26	3244-3247	way	_	_	
34-27	3248-3250	of	_	_	
34-28	3251-3254	yet	_	_	
34-29	3255-3262	further	_	_	
34-30	3263-3275	illustration	_	_	
34-31	3275-3276	,	_	_	
34-32	3277-3280	and	_	_	
34-33	3281-3283	as	_	_	
34-34	3284-3286	is	_	_	
34-35	3287-3296	disclosed	_	_	
34-36	3297-3299	in	_	_	
34-37	3300-3303	U.S	_	_	
34-38	3303-3304	.	_	_	

#Text=Pat.
35-1	3305-3308	Pat	_	_	
35-2	3308-3309	.	_	_	

#Text=No. 6,443,187 (the entire disclosure of which is hereby incorporated by reference into this specification), one may add to the reaction mixture derivatives of known tubulin-binding compounds in which a (poly)fluorobenzene, a fluoropyridine, or a fluoronitrobenzene moiety is incorporated or added to the structure.
36-1	3310-3312	No	_	_	
36-2	3312-3313	.	_	_	
36-3	3314-3323	6,443,187	_	_	
36-4	3324-3325	(	_	_	
36-5	3325-3328	the	_	_	
36-6	3329-3335	entire	_	_	
36-7	3336-3346	disclosure	_	_	
36-8	3347-3349	of	_	_	
36-9	3350-3355	which	_	_	
36-10	3356-3358	is	_	_	
36-11	3359-3365	hereby	_	_	
36-12	3366-3378	incorporated	_	_	
36-13	3379-3381	by	_	_	
36-14	3382-3391	reference	_	_	
36-15	3392-3396	into	_	_	
36-16	3397-3401	this	_	_	
36-17	3402-3415	specification	_	_	
36-18	3415-3416	)	_	_	
36-19	3416-3417	,	_	_	
36-20	3418-3421	one	_	_	
36-21	3422-3425	may	_	_	
36-22	3426-3429	add	_	_	
36-23	3430-3432	to	_	_	
36-24	3433-3436	the	_	_	
36-25	3437-3445	reaction	_	_	
36-26	3446-3453	mixture	_	_	
36-27	3454-3465	derivatives	_	_	
36-28	3466-3468	of	_	_	
36-29	3469-3474	known	_	_	
36-30	3475-3490	tubulin-binding	_	_	
36-31	3491-3500	compounds	_	_	
36-32	3501-3503	in	_	_	
36-33	3504-3509	which	_	_	
36-34	3510-3511	a	_	_	
36-35	3512-3513	(	_	_	
36-36	3513-3517	poly	_	_	
36-37	3517-3518	)	_	_	
36-38	3518-3531	fluorobenzene	_	_	
36-39	3531-3532	,	_	_	
36-40	3533-3534	a	_	_	
36-41	3535-3549	fluoropyridine	_	_	
36-42	3549-3550	,	_	_	
36-43	3551-3553	or	_	_	
36-44	3554-3555	a	_	_	
36-45	3556-3574	fluoronitrobenzene	_	_	
36-46	3575-3581	moiety	_	_	
36-47	3582-3584	is	_	_	
36-48	3585-3597	incorporated	_	_	
36-49	3598-3600	or	_	_	
36-50	3601-3606	added	_	_	
36-51	3607-3609	to	_	_	
36-52	3610-3613	the	_	_	
36-53	3614-3623	structure	_	_	
36-54	3623-3624	.	_	_	

#Text=These tubulin binding agents are described at columns 3-4 of U.S.
37-1	3625-3630	These	_	_	
37-2	3631-3638	tubulin	_	_	
37-3	3639-3646	binding	_	_	
37-4	3647-3653	agents	_	_	
37-5	3654-3657	are	_	_	
37-6	3658-3667	described	_	_	
37-7	3668-3670	at	_	_	
37-8	3671-3678	columns	_	_	
37-9	3679-3680	3	_	_	
37-10	3680-3681	-	_	_	
37-11	3681-3682	4	_	_	
37-12	3683-3685	of	_	_	
37-13	3686-3689	U.S	_	_	
37-14	3689-3690	.	_	_	

#Text=Pat.
38-1	3691-3694	Pat	_	_	
38-2	3694-3695	.	_	_	

#Text=No. 6,433,187, wherein it is disclosed that "The present invention provides a variety of agents capable of covalent attachment to tubulin.
39-1	3696-3698	No	_	_	
39-2	3698-3699	.	_	_	
39-3	3700-3709	6,433,187	_	_	
39-4	3709-3710	,	_	_	
39-5	3711-3718	wherein	_	_	
39-6	3719-3721	it	_	_	
39-7	3722-3724	is	_	_	
39-8	3725-3734	disclosed	_	_	
39-9	3735-3739	that	_	_	
39-10	3740-3741	"	_	_	
39-11	3741-3744	The	_	_	
39-12	3745-3752	present	_	_	
39-13	3753-3762	invention	_	_	
39-14	3763-3771	provides	_	_	
39-15	3772-3773	a	_	_	
39-16	3774-3781	variety	_	_	
39-17	3782-3784	of	_	_	
39-18	3785-3791	agents	_	_	
39-19	3792-3799	capable	_	_	
39-20	3800-3802	of	_	_	
39-21	3803-3811	covalent	_	_	
39-22	3812-3822	attachment	_	_	
39-23	3823-3825	to	_	_	
39-24	3826-3833	tubulin	_	_	
39-25	3833-3834	.	_	_	

#Text=Accordingly, the compounds are particularly useful as antimitotic agents for the treatment of cancer.
40-1	3835-3846	Accordingly	_	_	
40-2	3846-3847	,	_	_	
40-3	3848-3851	the	_	_	
40-4	3852-3861	compounds	_	_	
40-5	3862-3865	are	_	_	
40-6	3866-3878	particularly	_	_	
40-7	3879-3885	useful	_	_	
40-8	3886-3888	as	_	_	
40-9	3889-3900	antimitotic	_	_	
40-10	3901-3907	agents	_	_	
40-11	3908-3911	for	_	_	
40-12	3912-3915	the	_	_	
40-13	3916-3925	treatment	_	_	
40-14	3926-3928	of	_	_	
40-15	3929-3935	cancer	_	_	
40-16	3935-3936	.	_	_	

#Text=The compounds are derivatives of naturally-occurring antimitotic agents as well as other tubulin-interacting compounds.
41-1	3937-3940	The	_	_	
41-2	3941-3950	compounds	_	_	
41-3	3951-3954	are	_	_	
41-4	3955-3966	derivatives	_	_	
41-5	3967-3969	of	_	_	
41-6	3970-3989	naturally-occurring	_	_	
41-7	3990-4001	antimitotic	_	_	
41-8	4002-4008	agents	_	_	
41-9	4009-4011	as	_	_	
41-10	4012-4016	well	_	_	
41-11	4017-4019	as	_	_	
41-12	4020-4025	other	_	_	
41-13	4026-4045	tubulin-interacting	_	_	
41-14	4046-4055	compounds	_	_	
41-15	4055-4056	.	_	_	

#Text=Briefly, the compounds can be described as antimitotic agents having, for example, a pentafluorophenyl-sulfonamide group (C6 F5--SO.sub.2--NH--), a 2-fluoropyridyl group, a nitrofluorophenyl group or a dinitrofluorophenyl group.
42-1	4057-4064	Briefly	_	_	
42-2	4064-4065	,	_	_	
42-3	4066-4069	the	_	_	
42-4	4070-4079	compounds	_	_	
42-5	4080-4083	can	_	_	
42-6	4084-4086	be	_	_	
42-7	4087-4096	described	_	_	
42-8	4097-4099	as	_	_	
42-9	4100-4111	antimitotic	_	_	
42-10	4112-4118	agents	_	_	
42-11	4119-4125	having	_	_	
42-12	4125-4126	,	_	_	
42-13	4127-4130	for	_	_	
42-14	4131-4138	example	_	_	
42-15	4138-4139	,	_	_	
42-16	4140-4141	a	_	_	
42-17	4142-4171	pentafluorophenyl-sulfonamide	_	_	
42-18	4172-4177	group	_	_	
42-19	4178-4179	(	_	_	
42-20	4179-4181	C6	_	_	
42-21	4182-4184	F5	_	_	
42-22	4184-4185	-	_	_	
42-23	4185-4186	-	_	_	
42-24	4186-4192	SO.sub	_	_	
42-25	4192-4194	.2	_	_	
42-26	4194-4195	-	_	_	
42-27	4195-4196	-	_	_	
42-28	4196-4198	NH	_	_	
42-29	4198-4199	-	_	_	
42-30	4199-4200	-	_	_	
42-31	4200-4201	)	_	_	
42-32	4201-4202	,	_	_	
42-33	4203-4204	a	_	_	
42-34	4205-4206	2	_	_	
42-35	4206-4207	-	_	_	
42-36	4207-4220	fluoropyridyl	_	_	
42-37	4221-4226	group	_	_	
42-38	4226-4227	,	_	_	
42-39	4228-4229	a	_	_	
42-40	4230-4247	nitrofluorophenyl	_	_	
42-41	4248-4253	group	_	_	
42-42	4254-4256	or	_	_	
42-43	4257-4258	a	_	_	
42-44	4259-4278	dinitrofluorophenyl	_	_	
42-45	4279-4284	group	_	_	
42-46	4284-4285	.	_	_	

#Text=In each instance, the reactive fluorinated aromatic moiety is introduced into the parent compound by replacing an existing portion of the parent (e.g., an aromatic ring or lactone), by attaching to an available reactive functional group (e.g., hydroxyl, amino, carboxylic acid and the like), or by attaching to an otherwise unfunctionalized portion of the molecule.
43-1	4286-4288	In	_	_	
43-2	4289-4293	each	_	_	
43-3	4294-4302	instance	_	_	
43-4	4302-4303	,	_	_	
43-5	4304-4307	the	_	_	
43-6	4308-4316	reactive	_	_	
43-7	4317-4328	fluorinated	_	_	
43-8	4329-4337	aromatic	_	_	
43-9	4338-4344	moiety	_	_	
43-10	4345-4347	is	_	_	
43-11	4348-4358	introduced	_	_	
43-12	4359-4363	into	_	_	
43-13	4364-4367	the	_	_	
43-14	4368-4374	parent	_	_	
43-15	4375-4383	compound	_	_	
43-16	4384-4386	by	_	_	
43-17	4387-4396	replacing	_	_	
43-18	4397-4399	an	_	_	
43-19	4400-4408	existing	_	_	
43-20	4409-4416	portion	_	_	
43-21	4417-4419	of	_	_	
43-22	4420-4423	the	_	_	
43-23	4424-4430	parent	_	_	
43-24	4431-4432	(	_	_	
43-25	4432-4435	e.g	_	_	
43-26	4435-4436	.	_	_	
43-27	4436-4437	,	_	_	
43-28	4438-4440	an	_	_	
43-29	4441-4449	aromatic	_	_	
43-30	4450-4454	ring	_	_	
43-31	4455-4457	or	_	_	
43-32	4458-4465	lactone	_	_	
43-33	4465-4466	)	_	_	
43-34	4466-4467	,	_	_	
43-35	4468-4470	by	_	_	
43-36	4471-4480	attaching	_	_	
43-37	4481-4483	to	_	_	
43-38	4484-4486	an	_	_	
43-39	4487-4496	available	_	_	
43-40	4497-4505	reactive	_	_	
43-41	4506-4516	functional	_	_	
43-42	4517-4522	group	_	_	
43-43	4523-4524	(	_	_	
43-44	4524-4527	e.g	_	_	
43-45	4527-4528	.	_	_	
43-46	4528-4529	,	_	_	
43-47	4530-4538	hydroxyl	_	_	
43-48	4538-4539	,	_	_	
43-49	4540-4545	amino	_	_	
43-50	4545-4546	,	_	_	
43-51	4547-4557	carboxylic	_	_	
43-52	4558-4562	acid	_	_	
43-53	4563-4566	and	_	_	
43-54	4567-4570	the	_	_	
43-55	4571-4575	like	_	_	
43-56	4575-4576	)	_	_	
43-57	4576-4577	,	_	_	
43-58	4578-4580	or	_	_	
43-59	4581-4583	by	_	_	
43-60	4584-4593	attaching	_	_	
43-61	4594-4596	to	_	_	
43-62	4597-4599	an	_	_	
43-63	4600-4609	otherwise	_	_	
43-64	4610-4626	unfunctionalized	_	_	
43-65	4627-4634	portion	_	_	
43-66	4635-4637	of	_	_	
43-67	4638-4641	the	_	_	
43-68	4642-4650	molecule	_	_	
43-69	4650-4651	.	_	_	

#Text=Each of the reactive fluorinated aromatic moieties is capable of covalently modifying a cysteine thiol owing to the electrophilic nature of the fluoroaryl moiety and the leaving group character of the fluorine atom."
44-1	4652-4656	Each	_	_	
44-2	4657-4659	of	_	_	
44-3	4660-4663	the	_	_	
44-4	4664-4672	reactive	_	_	
44-5	4673-4684	fluorinated	_	_	
44-6	4685-4693	aromatic	_	_	
44-7	4694-4702	moieties	_	_	
44-8	4703-4705	is	_	_	
44-9	4706-4713	capable	_	_	
44-10	4714-4716	of	_	_	
44-11	4717-4727	covalently	_	_	
44-12	4728-4737	modifying	_	_	
44-13	4738-4739	a	_	_	
44-14	4740-4748	cysteine	_	_	
44-15	4749-4754	thiol	_	_	
44-16	4755-4760	owing	_	_	
44-17	4761-4763	to	_	_	
44-18	4764-4767	the	_	_	
44-19	4768-4781	electrophilic	_	_	
44-20	4782-4788	nature	_	_	
44-21	4789-4791	of	_	_	
44-22	4792-4795	the	_	_	
44-23	4796-4806	fluoroaryl	_	_	
44-24	4807-4813	moiety	_	_	
44-25	4814-4817	and	_	_	
44-26	4818-4821	the	_	_	
44-27	4822-4829	leaving	_	_	
44-28	4830-4835	group	_	_	
44-29	4836-4845	character	_	_	
44-30	4846-4848	of	_	_	
44-31	4849-4852	the	_	_	
44-32	4853-4861	fluorine	_	_	
44-33	4862-4866	atom	_	_	
44-34	4866-4867	.	_	_	
44-35	4867-4868	"	_	_	
